XRCC2 (N-term), 1-30 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-XRCC2 (N-term), 1-30 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityXRCC2 (N-term), 1-30
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatpeptide affinity purified
Size0.08 mL, 0.4 mL
Concentrationvial concentration: 0.5
ApplicationsWestern Blot (WB), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThis XRCC2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human XRCC2. This gene encodes a member of the RecA/Rad51-relatedprotein family that participates in homologous recombination tomaintain chromosome stability and repair DNA damage. This gene isinvolved in the repair of DNA double-strand breaks by homologousrecombination and it functionally complements Chinese hamster irs1,a repair-deficient mutant that exhibits hypersensitivity to anumber of different DNA-damaging agents.
Immunogenn/a
Other Names[DNA repair protein XRCC2; X-ray repair cross-complementing protein 2; XRCC2]
Gene, Accession #[XRCC2], Gene ID: 7516, NCBI: NP_005422.1, UniProt: O43543
Catalog #MBS9214164
Price$165, $370
Order / More InfoXRCC2 (N-term), 1-30 Antibody from MYBIOSOURCE INC.
Product Specific ReferencesLiu, Y., et al. Carcinogenesis 31(10):1762-1769(2010) Briggs, F.B., et al. Am. J. Epidemiol. 172(2):217-224(2010) Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010) Monsees, G.M., et al. Breast Cancer Res. Treat. (2010) In press : Lipkin, S.M., et al. Cancer Prev Res (Phila) 3(5):597-603(2010)
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.